The extension, released shortly before the flexibilities were set to expire at the end of 2025, gives regulators more time to ...
The Drug Enforcement Administration (DEA) published a yearlong extension of telemedicine prescribing flexibilities for ...
DEA extends telemedicine prescribing flexibilities through 2026, allowing remote controlled substance prescriptions without in-person visits.
The American Telemedicine Association announced that the U.S. Drug Enforcement Administration, or DEA, granted a 1-year ...
The third temporary extension, which prolongs the pandemic-era flexibilities through the end of 2025, is a relief for telehealth groups who had raised concerns about access to medications. During the ...
The Drug Enforcement Administration released a notice of proposed rulemaking that would create a three-tiered special registration system for the remote prescribing of controlled substances. An ...
The extension allows providers to continue remotely prescribing Schedule II–V controlled substances under specific conditions ...
The U.S. Drug Enforcement Agency and Health and Human Services announced the Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, meant to ...
The extension, released shortly before the flexibilities were set to expire at the end of 2025, gives regulators more time to finish permanent policies, the agencies said. During the COVID-19 pandemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback